

**Medicare Group (Q.S.C.)**  
**Condensed interim financial statements**  
**30 June 2018**

**Medicare Group (Q.S.C.)**

**Condensed interim financial statements**

**30 June 2018**

---

<b>Contents</b>	<b>Page(s)</b>
<b>Independent auditor's review report</b>	<b>1</b>
<b>Condensed interim financial statements:</b>	
Condensed interim statement of financial position	2
Condensed interim statement of profit or loss and other comprehensive income	3
Condensed interim statement of changes in equity	4
Condensed interim statement of cash flows	5
Notes to the condensed interim financial statements	6-14



KPMG  
25 C Ring Road  
PO Box 4473, Doha  
State of Qatar  
Telephone: +974 4457 6444  
Fax: +974 4442 5626  
Website: www.kpmg.com.qa

**INDEPENDENT AUDITOR'S REPORT ON REVIEW OF CONDENSED INTERIM FINANCIAL STATEMENT TO THE BOARD OF DIRECTORS OF MEDICARE GROUP Q.S.C.**

**Introduction**

We have reviewed the accompanying condensed interim statement of financial position of Medicare Group (Q.S.C) (the "Company"), as at 30 June 2018, the condensed statement of profit or loss and other comprehensive income, changes in equity and cash flows for the six-month period then ended and notes to the condensed interim financial statements.

The Board of directors of the Company is responsible for the preparation and presentation of these condensed interim financial statements in accordance with International Accounting Standard 34 "*Interim Financial Reporting*". Our responsibility is to express a conclusion on these condensed interim financial statements based on our review.

**Scope of review**

We conducted our review in accordance with the International Standard on Review Engagements 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*". A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim financial statements as at 30 June 2018 are not prepared, in all material respects, in accordance with IAS 34 "*Interim Financial Reporting*".

6 August 2018

Yacoub Hobeika  
KPMG

*Qatar Auditors Registry Number 289*  
*Licensed by QFMA : external Auditor's*  
*License No. 120153*

Medicare Group (Q.S.C.)

Condensed interim statement of financial position  
As at 30 June 2018

In Qatari Riyals

	Note	30 June 2018 (Reviewed)	31 December 2017 (Audited)
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property and equipment	3	901,003,329	909,271,180
Investments at fair value through other comprehensive Income		<u>43,298,956</u>	<u>45,618,518</u>
		<u>944,302,285</u>	<u>954,889,698</u>
<b>Current assets</b>			
Inventory		24,969,083	27,543,018
Accounts receivable and prepayments	7	97,490,503	99,082,484
Cash and cash equivalents	5	<u>33,712,613</u>	<u>102,119,126</u>
		<u>156,172,199</u>	<u>228,744,628</u>
<b>TOTAL ASSETS</b>		<b><u>1,100,474,484</u></b>	<b><u>1,183,634,326</u></b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital		281,441,000	281,441,000
Legal reserve		75,366,231	75,366,231
Fair value reserve		(10,990,669)	(11,861,482)
Revaluation surplus		530,550,754	534,148,663
Retained earnings		<u>47,181,098</u>	<u>122,654,883</u>
<b>Total equity</b>		<u>923,548,414</u>	<u>1,001,749,295</u>
<b>Non-current liabilities</b>			
Interest bearing loans	6	12,385,706	19,707,755
Employees' end of service benefits		<u>55,332,963</u>	<u>52,691,648</u>
		<u>67,718,669</u>	<u>72,399,403</u>
<b>Current liabilities</b>			
Accounts payable and accruals		93,602,631	94,132,067
Interest bearing loans	6	14,723,220	14,472,011
Retention payable		<u>881,550</u>	<u>881,550</u>
		<u>109,207,401</u>	<u>109,485,628</u>
<b>Total liabilities</b>		<u>176,926,070</u>	<u>181,885,031</u>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b><u>1,100,474,484</u></b>	<b><u>1,183,634,326</u></b>

These financial statements were approved and signed on behalf of the Board of Directors on 6 August 2018 by:

  
**Abdulla Bin Thani Bin Abdulla Al-Thani**  
 Chairman

  
**Khalid Mohammed Al-Emadi**  
 Chief Executive Officer

The attached notes from page 6 to page 14 form an integral part of these financial statements.

Medicare Group (Q.S.C.)

Condensed interim statement of profit or loss and other comprehensive income  
For the six month period ended 30 June 2018

In Qatari Riyals

	Note	30 June 2018 (Reviewed)	30 June 2017 (Reviewed)
Operating income		245,820,175	233,759,748
Operating costs	8	<u>(146,092,946)</u>	<u>(132,982,889)</u>
<b>Gross profit</b>		<u>99,727,229</u>	<u>100,776,859</u>
Income from deposit with an Islamic Bank		547,740	136,553
Other income	9	4,846,887	6,172,712
General and administrative expenses	10	(55,588,625)	(60,825,761)
Depreciation of property and equipment	3	(15,683,533)	(12,812,341)
Finance costs		<u>(600,538)</u>	<u>(858,835)</u>
<b>NET PROFIT FOR THE PERIOD</b>		<u><b>33,249,160</b></u>	<u>32,589,187</u>
Other comprehensive Income / (loss) for the period		<u>1,126,359</u>	<u>(5,758,605)</u>
<b>TOTAL COMIPREHENSIVE INCOME FOR THE PERIOD</b>		<u><b>34,375,519</b></u>	<u>26,830,582</u>
<b>BASIC AND DILUTED EARNING PER SHARE</b>			
(expressed in Qatari Riyals per share)	11	<u><b>1.18</b></u>	<u>1.16</u>

The attached notes from page 6 to page 14 form an integral part of these financial statements.

Medicare Group (Q.S.C.)

Condensed interim statement of changes in equity  
For the six month period ended 30 June 2018

In Qatari Riyals

	Share capital	Legal reserve	Fair value reserve	Revaluation surplus	Retained earnings	Total
Balance at 1 January 2018 (Audited)	281,441,000	75,366,231	(11,861,482)	534,148,663	122,654,883	1,001,749,295
Net profit for the period	-	-	-	-	33,249,160	33,249,160
Net change in fair value reserve (Investments at fair value through other comprehensive income)	-	-	1,126,359	-	-	1,126,359
Total comprehensive income	-	-	1,126,359	-	33,249,160	34,375,519
Dividends	-	-	-	-	(112,576,400)	(112,576,400)
Transfer of income on sale of investments at fair value through other comprehensive income	-	-	(255,546)	-	255,546	-
Transfer of depreciation of revalued assets	-	-	-	(3,597,909)	3,597,909	-
<b>Balance at 30 June 2018 (Reviewed)</b>	<b>281,441,000</b>	<b>75,366,231</b>	<b>(10,990,669)</b>	<b>530,550,754</b>	<b>47,181,098</b>	<b>923,548,414</b>
Balance at 1 January 2017 (Audited)	281,441,000	67,366,036	(3,296,998)	541,344,487	129,889,656	1,016,744,181
Net profit for the period	-	-	-	-	32,589,187	32,589,187
Net change in fair value reserve (Investments at fair value through other comprehensive income)	-	-	(5,758,605)	-	-	(5,758,605)
Total comprehensive income	-	-	(5,758,605)	-	32,589,187	26,830,582
Dividends	-	-	-	-	(84,432,300)	(84,432,300)
Balance at 30 June 2017 (Reviewed)	281,441,000	67,366,036	(9,055,603)	541,344,487	78,046,543	959,142,463

The attached notes from page 6 to page 14 form an integral part of these financial statements



Medicare Group (Q.S.C.)

Condensed interim statement of cash flows  
For the six month period ended 30 June 2018

In Qatari Riyals

	Note	30 June 2018 (Reviewed)	30 June 2017 (Reviewed)
<b>OPERATING ACTIVITIES</b>			
Net profit for the period		33,249,160	32,589,187
<i>Adjustments for:</i>			
- Depreciation of property and equipment	3	15,683,533	12,812,341
- Provision for employees' end of service benefits		4,904,617	4,233,461
- Provision for obsolete and slow moving inventory	8	1,557,744	1,310,374
- Finance costs		600,538	858,835
- Impairment allowance for bad and doubtful debts	10	8,827,830	17,211,585
- Trade receivables write off		(681,956)	(7,447,256)
- Income from deposits with Islamic banks		(547,740)	-
- Dividends income	9	(2,818,990)	(2,656,477)
Operating profit before working capital changes		<u>60,774,736</u>	<u>58,912,050</u>
<i>Changes in:</i>			
- Inventory		1,016,191	2,248,779
- Accounts receivable and prepayments		(6,553,893)	16,003,616
- Accounts payable and accruals		(2,066,464)	7,192,851
- Retention payable		-	54,399
		<u>53,170,570</u>	<u>84,411,695</u>
Employees' end of service benefits paid		(2,263,302)	(1,834,117)
Paid to contribution to social and sports fund		(2,000,049)	-
Finance costs paid		(600,538)	(858,835)
<b>Net cash from operating activities</b>		<u>48,306,681</u>	<u>81,718,743</u>
<b>INVESTING ACTIVITIES</b>			
Acquisition of property and equipment	3	(7,415,682)	(33,483,088)
Net movement in term deposits		50,065,748	-
Proceeds on sale of investments at fair value through other comprehensive income		3,445,919	-
Income from deposits with Islamic banks		547,740	-
Purchase of investments		-	(3,765,355)
Dividends income received		2,818,990	2,656,477
<b>Net cash from / (used in) investing activities</b>		<u>49,462,715</u>	<u>(34,591,966)</u>
<b>FINANCING ACTIVITIES</b>			
Cash dividends paid		(109,039,320)	(82,274,942)
Repayments of loans		(7,070,841)	(9,438,586)
<b>Net cash used in financing activities</b>		<u>(116,110,161)</u>	<u>(91,713,528)</u>
<b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>		(18,340,765)	(44,586,751)
Cash and cash equivalents at 1 January		52,053,378	96,864,639
<b>CASH AND CASH EQUIVALENTS AT 30 JUNE</b>	5	<u><b>33,712,613</b></u>	<u>52,277,888</u>

The attached notes from page 6 to page 14 form an integral part of these financial statements.

## Medicare Group (Q.S.C.)

### Notes to the condensed interim financial statements For the six month period ended 30 June 2018

---

#### 1. REPORTING ENTITY

Medicare Group Q.S.C. (formerly known as Al Ahli Specialized Hospital Company Q.S.C) is a Qatari Shareholding Company incorporated on 30 December 1996 under commercial registration number 18895. The Company is primarily involved in operating a specialized hospital and to promoting medical services in the State of Qatar.

The interim condensed financial statements of the Company for the six months ended 30 June 2018 were authorized for issue in accordance with a resolution of the Board of Directors on 6 August 2018.

#### 2. BASIS OF PREPARATION

##### (a) Statement of compliance

These interim condensed financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting.

The condensed interim financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Company's annual financial statements as at and for the year ended 31 December 2017. The results for the six months ended 30 June 2018 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2018.

The condensed interim financial statements are presented in Qatari Riyals, which is the Company's functional and presentational currency.

##### (b) Uses of estimates and judgements

In preparing these condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the financial statements as at and for the year ended 31 December 2017.

##### (c) Significant accounting policies

The accounting policies and methods of computation adopted in the preparation of the condensed interim financial information are the same as those followed in the preparation of the Company's financial statements as at and for the year ended 31 December 2017, except as noted below:

During the current period, the Company adopted the below new and amended International Financial Reporting Standards ("IFRS") and improvements to IFRS that are effective for annual periods beginning on 1 January 2018:

- *IFRS 15 "Revenue from Contracts with Customers"*
- *Amendments to IFRS 2 "Classification and Measurement of Share-based Payment Transactions"*
- *Amendments to IAS 40 "Transfers of Investment Property"*
- *Annual improvements to IFRSs 2014-2016 Cycle "Amendments to IFRS 1 and IAS 28"*
- *IFRIC 22 Foreign Currency Transactions and Advances consideration.*

The adoption of the above new and amended IFRS and improvements to IFRS had no significant impact on the condensed interim financial statements as mentioned below:

##### **IFRS 15 "Revenue from Contracts with Customers"**

IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It replaced IAS 18 "Revenue" and related interpretations.



**2. BASIS OF PREPARATION (CONTINUED)****(c) Significant accounting policies (continued)****IFRS 15 “Revenue from Contracts with Customers” (continued)**

The details of the new significant accounting policies and the nature of the changes to previous accounting policies in respect of the Company’s significant revenue generating activities are set out below:

Type of services	Nature, timing of satisfaction of performance obligations, significant payment terms	Nature of change in accounting policy.
Medical services:	The revenue is recognized when the related medical services are performed.	No significant impact.
Sale of medications:	The revenue is recognized when the medications are transferred to the patient.	No impact.

**3. PROPERTY AND EQUIPMENT**

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Net book value at the beginning of the period	909,271,180	876,492,930
Additions	7,415,682	60,969,391
Disposals	-	(101,000)
Depreciation charge for the period / year	(15,683,533)	(28,191,141)
Accumulated Depreciation of disposals	-	101,000
Net book value at the end of the period	<u><b>901,003,329</b></u>	<u>909,271,180</u>

**4. DIVIDENDS**

At the Annual General Meeting held on 20 March 2018, the shareholders of the Company approved a cash dividend of QR 4 per share relating to the year ended 31 December 2017. The total cash dividend amounted to QAR 112,576,400 (30 June 2017: QAR 84,432,300).

**5. CASH AND CASH EQUIVALENTS**

Cash and cash equivalents comprise of the following:

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Cash in hand	398,327	404,360
Bank balances	33,314,286	21,649,018
Short term deposits *	-	80,065,748
Total cash and bank balances	33,712,613	102,119,126
Less: Deposits with original maturities of less than 90 days	-	(50,065,748)
Cash and cash equivalents	<u><b>33,712,613</b></u>	<u>52,053,378</u>

\* Deposits held as at 31 December 2017 carried a profit rate of 3%.

## 6. INTREST BEARING LOANS

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Term loan (i)	27,108,926	34,179,766
	<u><b>27,108,926</b></u>	<u>34,179,766</u>

Presented in the statement of financial position as follows:

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Current portion	14,723,220	14,472,011
Non-current portion	12,385,706	19,707,755
	<u>27,108,926</u>	<u>34,179,766</u>

Notes:

- (i) This amount represents a facility obtained from a Qatar based Islamic Bank to finance the purchase of a building for employee accommodation. The loan is repayable in 60 monthly installments and matures on 30 April 2020. The loan is secured through the mortgage of the building purchased.

## 7. ACCOUNTS RECEIVABLE AND PREPAYMENTS

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Gross trade receivables	152,279,598	158,910,937
Advances to suppliers	10,339,601	6,992,179
Due from investment securities broker	3,996,665	550,398
Refundable deposits	1,284,832	1,251,164
Prepaid expenses	8,700,389	3,210,871
Staff Receivables	1,385,343	1,070,428
Others	2,745,653	2,192,211
	<u><b>180,732,081</b></u>	<u><b>174,178,188</b></u>
Less : Allowance for impairment of trade receivables	<u>(83,241,578)</u>	<u>(75,095,704)</u>
	<u><b>97,490,503</b></u>	<u>99,082,484</u>

The movement in the allowance for impairment of trade accounts receivables is as follows:

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
At 1 January	75,095,704	66,208,984
Provision during the period	8,827,830	16,000,000
Write off	<u>(681,956)</u>	<u>(7,113,280)</u>
	<u>83,241,578</u>	<u>75,095,704</u>

## 8. OPERATING COSTS

	<b>30 June 2018 (Reviewed)</b>	30 June 2017 (Reviewed)
Staff costs	93,127,580	85,402,866
Medication and surgical costs	37,762,100	37,436,589
Community doctors expenses	5,921,706	5,327,588
Rent expenses	3,600,000	-
Food costs	1,616,108	1,326,779
Provision for slow moving inventory	1,557,744	1,310,374
Utilities	1,313,586	1,301,852
Fuel costs	708,321	446,684
Other direct costs	485,801	430,157
	<b><u>146,092,946</u></b>	<b><u>132,982,889</u></b>

## 9. OTHER INCOME

	<b>30 June 2018 (Reviewed)</b>	30 June 2017 (Reviewed)
Dividend income	2,818,990	2,656,477
Rental income	1,231,032	1,357,383
Catering income	224,267	330,278
Gain on foreign currency exchange	54,741	426,531
Miscellaneous income	517,857	1,402,043
	<b><u>4,846,887</u></b>	<b><u>6,172,712</u></b>

**10. GENERAL AND ADMINISTRATIVE EXPENSES**

	<b>30 June 2018 (Reviewed)</b>	30 June 2017 (Reviewed)
Staff costs	29,319,446	27,557,739
Impairment allowance for bad and doubtful debts	8,827,830	17,211,585
Maintenance and repairs	3,524,616	3,446,959
Outsourcing call center and helpers	2,733,248	2,351,248
Telephone and fax	1,761,630	1,507,427
Security and cleaning	1,562,172	1,392,120
Advertisement and promotions	1,353,960	1,230,545
Insurance	1,335,975	841,360
Board of Directors' remuneration	1,160,415	1,089,440
IT development	856,183	648,023
Legal and professional fees	706,714	584,447
Printing and stationery	563,590	858,362
Charity	526,638	166,066
Bank charges	462,204	536,711
Government expenses	356,160	650,216
Medical Waste	303,005	229,700
Others	234,839	523,813
	<b><u>55,588,625</u></b>	<b><u>60,825,761</u></b>

**11. BASIC AND DILUTED EARNINGS PER SHARE**

Basic earnings per share is calculated by dividing the net profit for the period by the weighted average number of ordinary shares outstanding during the period as follows:

	<b>30 June 2018 (Reviewed)</b>	30 June 2017 (Reviewed)
Net profit for the period	<b><u>33,249,160</u></b>	<b><u>32,589,187</u></b>
Weighted average number of ordinary shares outstanding during the period	<b><u>28,144,100</u></b>	<b><u>28,144,100</u></b>
Basic and diluted earnings per share	<b><u>1.18</u></b>	<b><u>1.16</u></b>

There were no potentially dilutive shares outstanding at any time during the period and, therefore, the dilutive earnings per share is equal to the basic earnings per share.



**12. CONTINGENCIES AND COMMITMENTS****a) Contingent liabilities**

The Company had the following contingent liabilities from which it is anticipated that no material liabilities will arise:

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Bank guarantees	489,734	320,444

**b) Legal claims**

As at 30 June 2018, various legal claims were filed by patients and other third parties against the Company in the form of malpractice compensation claims and other miscellaneous claims. In the opinion of the Company's lawyers, it would be difficult to reliably estimate the compensation that may be awarded. However, the Company's lawyers believe, based on previous experience and available information, that the Company is unlikely to incur losses as a result of these claims. Moreover, the Company has adequate malpractice insurance coverage in place to protect itself and its Doctors in the event of any judgment against them. No provision has been made in the financial statements.

**c) Claims from NHIC**

The Company submitted claims to National Health Insurance Company ("NHIC") with respect to services provided to patients under the NHIC scheme. Claims pertaining to services provided have been submitted to the NHIC in accordance with the agreement between NHIC and the services providers. As of the reporting date, the claims submitted by the Company are yet to be formally approved by the NHIC. The balance with NHIC is carried at the management's best estimate and the management is of the view that the net carrying balance is recoverable in full.

**d) Commitments under lease agreements**

The Company has entered into operating leases for staff accommodation. These leases have been negotiated for periods of less than 1 year.

The future minimum rentals payable under non-cancellable operating leases as at 30 June 2018, 31 December 2017 are as follows:

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Within one year	8,109,501	2,432,400
More than one year and less than 5 years	12,938,055	-
	<b>21,047,556</b>	<b>2,432,400</b>

**e) Capital commitments**

The capital commitments of the company as at 30 June 2018 amounted to QR **80,580,583** (31 December 2017: 68,970,863) it relates primarily to contracts entered for the development of buildings

**13. RELATED PARTY TRANSACTIONS**

Related parties represent major shareholders, directors and key management personnel of the Company, and entities controlled, jointly controlled or significantly influenced by such parties. Pricing policies and terms of these transactions are approved by the Company's management.

Transactions with related parties included in the unaudited interim statement of income are as follows:

	<b>30 June 2018 (Reviewed)</b>	30 June 2017 (Reviewed)
Interest income	<u>547,738</u>	<u>136,553</u>
Rental income	<u>222,282</u>	<u>222,282</u>
Bank charges	<u>(41,468)</u>	<u>(40,257)</u>
Interest expenses	<u>(600,538)</u>	<u>(858,835)</u>
Insurance expenses	<u>(4,068,960)</u>	<u>(845,427)</u>

Transactions with related parties included in the unaudited interim statement of financial position are as follows:

	<b>30 June 2018 (Reviewed)</b>	31 December 2017 (Audited)
Bank balances	<u>32,148,041</u>	<u>20,795,993</u>
Short term deposits	<u>-</u>	<u>80,000,000</u>
Interest receivable	<u>-</u>	<u>436,439</u>
Interest bearing loans	<u>27,108,926</u>	<u>34,179,766</u>

**Compensation of key management personnel and the Board of Directors' remuneration**

The remuneration of the Board of Directors and members of key management during the period was as follows:

	<b>30 June 2018 (Reviewed)</b>	30 June 2017 (Reviewed)
Board of Directors' remuneration	1,160,415	1,089,440
Total key management staff benefits	<u>2,115,875</u>	<u>1,914,500</u>
	<u><b>3,276,290</b></u>	<u><b>3,003,940</b></u>

**14. FAIR VALUE OF FINANCIAL INSTRUMENTS****Fair Values**

Set out below is a comparison of the carrying amounts and fair value of the Company's financial instruments as at 30 June 2018 and 31 December 2017:

	Carrying amounts		Fair values	
	30 June 2018 (Reviewed)	31 December 2017 (Audited)	30 June 2018 (Reviewed)	31 December 2017 (Audited)
<b>Financial assets</b>				
Bank balances	33,314,286	101,714,766	33,314,286	101,714,766
Trade and other receivables	74,420,028	85,436,059	74,420,028	85,436,059
Investments at fair value through other comprehensive	43,298,956	45,618,518	43,298,956	45,618,518
<b>Financial Liabilities</b>				
Trade payables	25,114,176	28,801,308	25,114,176	28,801,308
Retention payable	881,550	881,550	881,550	881,550
Interest bearing loans	27,108,926	34,179,766	27,108,926	34,179,766

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

- The carrying amounts of bank balances, trade and other receivables, trade and other payables and retention payable approximate their fair values largely due to the short-term maturities of these instruments.
- The fair value of quoted investments is based on price quotations at the end of the reporting period.

There were no transfers between Level 1 and Level 2 fair value measurements during the period, and no transfers into or out of Level 3 fair value measurements during the six-month period ended 30 June 2018.

**Fair value hierarchy**

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique.

- Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities;
- Level 2: Other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and
- Level 3: Techniques that use inputs that have a significant effect on the recorded fair values are not based on observable market data.

**14. FAIR VALUE OF FINANCIAL INSTRUMENTS (CONTINUED)**

As at 30 June 2018 and 31 December 2017, the Company held the following classes of financial instruments measured at fair value:

	30 June 2018 (Reviewed)	Level 1	Level 2	Level 3
<b>Financial assets</b>				
Investments at fair value through other comprehensive income *	43,298,956	43,298,956	-	-
	<u>43,298,956</u>	<u>43,298,956</u>	<u>-</u>	<u>-</u>
<b>Non-financial assets</b>				
Revalued land and building	776,593,278	-	-	776,593,278
	<u>776,593,278</u>	<u>-</u>	<u>-</u>	<u>776,593,278</u>
	31 December 2017 (Audited)	Level 1	Level 2	Level 3
<b>Financial assets</b>				
Financial assets at fair value through other comprehensive income	45,618,518	45,618,518	-	-
	<u>45,618,518</u>	<u>45,618,518</u>	<u>-</u>	<u>-</u>
<b>Non-financial assets</b>				
Revalued land and building	783,648,268	-	-	783,648,268
	<u>783,648,268</u>	<u>-</u>	<u>-</u>	<u>783,648,268</u>

**15. SEGMENT INFORMATION**

The Company is engaged in providing health care services and operates only in the State of Qatar, hence segmental disclosure based on business and geographical segments are not applicable.